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Abstract
Background: Increased prevalence of metabolic syndrome (MS) is observed in psoriasis. Metformin has shown
improvement in cardiovascular risk factors while pioglitazone demonstrated anti proliferative, anti-inflammatory and
anti angiogenic effects. Study objective is to evaluate the efficacy and safety of Insulin sensitizers (metformin and
pioglitazone) in psoriasis patients with metabolic syndrome (MS).
Methods: Single centre, parallel group, randomized, study of metformin, pioglitazone and placebo in psoriasis
patients with MS.
Results: Statistically significant improvement was observed in Psoriasis Area and Severity Index (PASI), Erythema,
Scaling and Induration (ESI) and Physician global assessment (PGA) scores in pioglitazone (p values – PASI = 0.001,
ESI = 0.002, PGA = 0.008) and metformin groups (p values – PASI = 0.001, ESI = 0.016, PGA = 0.012) as compared to
placebo. There was statistically significant difference in percentage of patients achieving 75 % reduction in PASI and
ESI scores in metformin (p value – PASI = 0.001, ESI = 0.001) and pioglitazone groups (p vaue – PASI = 0.001, ESI = 0.
001). Significant improvement was observed in fasting plasma glucose (FPG) and triglycerides levels in metformin
and pioglitazone arms. Significant improvement was noted in weight, BMI, waist circumference, FPG, triglycerides
and total cholesterol after 12 weeks of treatment with metformin while pioglitazone showed improvement in FPG,
triglyceride levels, systolic blood pressure (SBP), diastolic blood pressure (DBP), total cholesterol and LDL cholesterol
levels. There was no difference in pattern of adverse drug reaction in three groups.
Conclusion: Insulin sensitizers have shown improvement in the parameters of MS as well as disease severity in
psoriasis patients.
Trial registration: CTRI Registration Number: CTRI/2011/12/002252. Registered on 19/12/2011.
Keywords: Psoriasis, Metabolic syndrome, Insulin sensitizers, Metformin, Pioglitazone
Abbreviations: ACE inhibitors, Angiotensin Converting Enzyme Inhibitors; ALT, Alanine Transaminase;
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2, Extracellular Signal-related Kinase 1/2; ESI, Erythema, Scaling and Induration; FPG, Fasting Plasma Glucose;
HDL, High density lipoprotein; HTN, Hypertension; IL, Interleukin; LDL, Low Density Lipoprotein; LOCF, Last
Observation Carry Forward; MS, Metabolic Syndrome; NCEP ATP III, National Cholesterol Education Program’s Adult
Treatment Panel III; OD, Once Daily; PASI, Psoriasis Area and Severity Index; PFA, Physician Global Assessment; PPAR-
γ, Peroxisome Proliferator-activated receptor- γ; SBP, Systolic Blood Pressure; SD, Standard Deviation; TNF-α, Tumor
Necrosis Factor- α; TZD, Thiazolidinedione
Background
Psoriasis is a chronic, inflammatory multisystemic dis-
order with genetic basis affecting 2-3 % of world popula-
tion and affecting about 0.4 % of Asians [1]. Psoriasis
has been found to be associated more commonly with
obesity, metabolic syndrome (MS) [1, 2], diabetes melli-
tus [3] and increased cardiovascular (CVS) mortality and
morbidity [4–6]. Metabolic syndrome (MS) is a cluster
of risk factors including central obesity, atherogenic dys-
lipidemia, hypertension and glucose intolerance and is a
strong predictor of cardiovascular diseases, diabetes and
stroke [7–9]. Many cytokines (e.g. interferon-γ, TNF-α,
IL-6, IL-8, IL-12, IL-17, IL-19 and IL-23) involved in the
pathogenesis of psoriasis are also known to contribute to
the cascade of metabolic syndrome such as hyperten-
sion, dyslipidemia and insulin resistance [10]. Prodiffer-
entiating, antiproliferative, anti-inflammatory and
antiangiogenic effects of Peroxisome proliferator-
activated receptor- γ (PPAR-γ) ligands may potentially
have beneficial role in psoriasis [11–13] as exemplified
by demonstrated efficacy of Thiazolidinediones (TZDs)
in treatment of psoriasis [14–18]. Metformin is an ‘insu-
lin sensitiser’, lowers glucose levels without increasing in-
sulin secretion. It has shown additional beneficial effects
in adults with type 2 diabetes, including weight reduc-
tion, decreasing hyperinsulinemia, improving lipid pro-
files, augmented fibrinolysis and enhanced endothelial
function [19–21], that all are usual metabilic abnormal-
ities observed in subjects with MS. Therfore we antici-
pated that such pharmacological effects observed with
metformin might be of use in psoriatic patients with
MS. To the best of our knowledge no study till date has
evaluated metformin and pioglitazone head to head in
patients of psoriasis with MS. Present study was planned
as comparative evaluation of safety & efficay of metfor-
min with pioglitazone in placebo controlled setting in
patients of psoriasis with MS.
Methods
Clinical trial design
Study was approved by Institute Ethics committee, Post
Graduate Institute of Medical Education and Research.
This clinical trial was a single centre, parallel group, ran-
domized, open label with blinded endpoint assessment
of metformin, pioglitazone and placebo in psoriasis
patients with MS satisfying inclusion and exclusion cri-
teria. Our study is a part of larger study in which we
evaluated the prevalence of MS in psoriasis. Then psor-
iasis patients having MS were divided into systemic
(moderate to severe psoriasis, randomized into metfor-
min and placebo arms) and topical treatment cohort
(mild to moderate psoriasis, randomized into metformin,
piolglitazone and placebo arms) and were evaluated for
the effect of insulin sensitizers on disease parameters
and MS. In this paper, we have discussed the results of
topical treatment cohort.
All patients visiting psoriasis clinic at our Institute
were screened for MS and other eligibility criteria.
Both males and females, > 18 years with plaque psor-
iasis [mild to moderate disease severity (<10 % of
body surface area) [22], on treatment (had taken even
a single application of topical therapy in the past)
and treatment naïve (no past history of treatment for
their disease)] and having MS i.e. the presence of
three or more criteria of the modified National Chol-
esterol Education Program’s Adult Treatment Panel
III (NCEP ATP III) [23]: waist circumference > 90 cm
in men and > 80 cm in women, hypertriglyceridemia ≥
150 mg/dl, high density lipoprotein (HDL) cholesterol
< 40 mg/dl in males and < 50 mg/dl in females, blood
pressure ≥ 130/85 mmHg and fasting plasma glucose ≥
110 mg/dl and willing to provide written informed
consent were included in the study. Patients with se-
vere disease, on topical therapy other than coal tar,
pregnant or nursing women, significant hepatic im-
pairment (serum bilirubin, AST, ALT and alkaline
phosphatase >1.5 times the upper limit of normal),
renal insufficiency - serum creatinine ≥1.5 mg/dL
(men) or ≥1.4 mg/dL (women) and contraindication
to metformin and pioglitazone were excluded from
the study.
Clinical examination including psoriasis area and se-
verity index (PASI) [22] scores and erythema, scaling
and induration (ESI) scoring [24] was done. Clinical
photographs of patients were taken at baseline and post
treatment. Baseline investigations were done and eligible
patients were randomized in an open label manner to ei-
ther placebo (empty gelatin capsules), metformin
1000 mg once daily (O.D) or pioglitazone 30 mg O.D
groups for a period of 12 weeks, after taking written
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informed consent. All patients were given standard top-
ical 5 % coal tar ointment in addition to study drugs.
The randomization codes were computer generated.
Randomization codes were concealed in an opaque en-
velope. The drug dispensation was done by a person
who was not involved with the assessment of the study
endpoints. Evaluation for efficacy parameters was done
at 0 and 12 weeks. Safety evaluation was also done
throughout the study.
Efficacy evaluation
Blinded end points assessment of the efficacy parameters
was done at 12 weeks. Psoriasis lesions were evaluated
using psoriasis area and severity index (PASI) scores and
erythema, scaling and induration (ESI) score [24]. Each
component of ESI was graded from 0 to 3; 0 – clear, 1 -
mild, 2 - moderate, 3 - severe. The most severe condi-
tion was given 9 points whereas absence of disease been
given 0 points.
Also all the parameters of MS as defined by modified
National Cholesterol Education Program’s Adult Treat-
ment Panel III (NCEPIII) criteria [23] were assesed at
baseline and 12 weeks. Serum IL-6 and TNF-α levels
was done at 0 and 12 weeks in subgroup (10, 7 and 9 pa-
tients in placebo, metformin and pioglitazone groups re-
spectively) of patients by Human ELISA kit (RayBiotech,
Inc. Georgia. USA).
The primary efficacy end point was mean change in
PASI, ESI and PGA scores from baseline after 12 weeks
of therapy between three treatment groups given along
with standard treatment for psoriasis. The Secondary ef-
ficacy end point were number of parameters of MS im-
proved, change in individual parameters of MS, IL -6
and TNF – α from baseline after 12 weeks of treatment
with metformin, pioglitazone or placebo. The change in
Physician Global Assessment (PGA) from baseline and
percentage of patients achieving 75 % reduction in ESI
and PGA score in the three treatment groups were other
end points.
Sample size calculation
Assuming a standard deviation of 2 in PASI scores, and
a difference of 2 in PASI score between drug and pla-
cebo arm at 12 weeks to be clinically significant at α =
0.05 and with 80 % power, a sample size of 16 patients
per group has been calculated and with a dropout rate
of about 20 %, 19 patients will be required to be in-
cluded in each group.
Statistical analysis
Data was expressed as Mean ± SD (95 % confidence inter-
vals), numbers (percentages) and median (interquartile
range). Baseline characteristics between three treatment
groups were compared using one way ANOVA for
numerical variables and Chi-Square test for categorical
variables. Analysis was carried out using intention to treat
principle.
Mean changes in PASI, ESI and PGA scores at
12 weeks from baseline between three treatment groups
were compared using One way ANOVA followed by
post hoc Scheffe. Chi-Square test or Fischer’s Exact test
was used to compare the categorical variables. Intra
group comparison of mean changes in individual param-
eters of MS and lipid profile was carried out by paired
T-test and inter group comparison by One way ANOVA.
Difference in changes in serum levels of IL-6 and TNF-α
between the groups was done by One way ANOVA.
Results were analyzed as Intention-to-treat analysis
with last observation carry forward (LOCF). A two-sided
P-value less than 0.05 was considered as statistically
significant.
Results
A total of 83 consecutive adult psoriasis patients with
MS were screened from June 2010 to April 2011 (Fig. 1).
Out of 83 patients, 23 were excluded from the study. 23,
16 and 21 patients were randomized to placebo, pioglita-
zone and metformin treatment groups respectively. Dis-
position of patients and reasons for withdrawal were
summarized in Fig. 1. Hence, 21 patients in placebo
arm, 16 in pioglitazone and 18 patients in metformin
arm completed the study. As Intention to treat analysis
with last observation carry forward (LOCF) was done, so
all the subjects as randomized were included for final
analysis.
No significant difference was observed in baseline
demographics and MS characteristics among three treat-
ment groups except past history of remission (Table 1).
ESI and PGA scores and parameters of Metabolic
Syndrome (MS)
Statistically significant improvement was observed in
PASI, ESI and PGA scores in pioglitazone (P values –
PASI = 0.001, ESI = 0.002, PGA = 0.008) and metformin
groups (P values – PASI = 0.001, ESI = 0.016, PGA =
0.012) as compared to placebo (Fig. 2). There was statis-
tically significant difference in percentage of parameters
of MS improved following 12 weeks of treatment in pio-
glitazone (15 %) and metformin (16.2 %) groups as com-
pared to placebo (3.5 %) (Fig. 3). Statistically significant
difference in percentage of patients achieving 75 % re-
duction in PASI and ESI scores in metformin (p value –
PASI = 0.001, ESI = 0.001) and pioglitazone groups (p
value – PASI = 0.001, ESI = 0.001) (Fig. 4). Statistically
significant improvement is observed in FPG, total chol-
esterol and triglycerides levels (Table 2) in metformin
and pioglitazone arms as compared to placebo. Signifi-
cant improvement was also observed in percentage of
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patients achieving 75 % reduction in PGA scores (Fig. 4)
and change in weight and waist circumference in met-
formin group as compared to placebo (Table 2). Signifi-
cant improvement was observed in weight, BMI, waist
circumference, FPG, triglycerides and total cholesterol
after treatment with metformin (Table 2). Similarly im-
provement was seen in FPG, triglyceride levels, systolic
blood pressure (SBP), diastolic blood pressure (DBP),
total cholesterol and LDL cholesterol levels after treat-
ment with pioglitazone for 12 weeks (Table 2). No sig-
nificant change in the IL-6 and TNF-α levels among
three groups (Fig. 5).
No significant difference in the mean number of ad-
verse events in three groups except for weight gain be-
tween metformin and pioglitazone (Table 3).
Discussion
Baseline characteristics were similar among three treat-
ment groups except for percentage of individuals having
remission. The difference observed in baseline character-
istic is unlikely to be of clinical significance and could
not have accounted for the higher efficacy observed in
metformin and pioglitazone groups in comparison to
placebo group. All patients were given topical 5 % coal
tar treatment. As the compliance achieved is around
90 %, which is ensured by direct questioning and pill
count, it is less likely that topical treatment with 5 %
coal tar would have resulted in the differences in efficacy
among three treatment groups. In our study, metformin
and pioglitazone cause significant improvement in PASI,
ESI and PGA scores as compared to placebo.
In metformin, pioglitazone and placebo group, 52.4 %,
50 % and 17.4 % of the patients had complete improve-
ment in MS respectively (metformin vs placebo – OR
(95 % CI), 5.2 (1.3–20.7), P value = 0.019; pioglitazone vs
placebo – (OR (95 % CI) = 4.8 (1.1–20.4), P value =
0.036; metformin vs pioglitazone – (OR (95 % CI) = 0.9
(0.2–3.3), P value = 0.886). Therefore, metformin and pi-
oglitazone beneficial effect on MS parameters might be
accounted for the improved efficacy in psoriasis disease
itself.
Clinical studies had also demonstrated the proof of ef-
ficacy of TZDs in psoriasis. Pioglitazone had demon-
strated superior efficacy to placebo group alone as well
as in combination therapy with acitretin in psoriasis pa-
tients [14, 15]. Two open label studies [16, 17] had dem-
onstrated marked improvement in psoriasis lesions with
troglitazone in chronic plaque type psoriasis patients.
Robertshaw and Friedman [18] have also demonstrated
excellent improvement with pioglitazone in 4 out of 5
patients with chronic plaque type psoriasis in an open
label, pilot study.
Study done by Bongartz et al (2005) with pioglitazone
60 mg/day for 12 weeks in psoriatic arthritis patients
with tender and swollen joints, demonstrated 60 % of
the patients met the psoriatic arthritis response criterion.
Mean percentage reduction in PASI was 38 %, along
with median tender joint count decreased from 12–4
and median swollen joint count from 5 to 2 (P <0.05 for
both) [25]. The observed higher percentage reduction in
ESI and PGA scores in our study is thus expected and is
a demonstration of pioglitazone efficacy.
Fig. 1 Flowchart of the patients enrolled in the study depicting enrollment, withdrawal and follow up of the subjects
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Table 1 Baseline characteristics of three treatment groups
Baseline characteristics Placebo (n = 23) Metformin (n = 21) Pioglitazone (n = 16) p-value
Age (years) Mean (±SD) 46.9 (±10.4) 45.1 (±13.0) 44.0 (±12.9) 0.747
Male/Females, n (%) 14/9 (60.9/39.1) 12/9 (57.1/42.9) 9/7 (56.3/43.7) 0.950
Total duration of disease (years) Mean (±SD) 9.1 (±8.6) 6.0 (±6.9) 6.9 (±11.2) 0.492
Seasonal Exacerbation, n (%) 13 (56.5) 13 (61.9) 6 (37.5) 0.313
Seasonal improvement, n (%) 13 (56.5) 13 (61.9) 5 (31.3) 0.152
Remission, n (%) 21 (91.3) 11 (52.4) 10 (62.5) 0.014
Nail involvement, n (%) 17 (73.9) 13 (61.9) 12 (75.0) 0.602
Joint involvement, n (%) 7 (30.4) 5 (23.8) 4 (25.0) 0.870
DM, n (%) 2 (8.7) 3 (14.3) 3 (18.6) 0.653
HTN, n (%) 11 (47.8) 10 (47.6) 5 (31.3) 0.523
Family H/O Psoriasis, n (%) 4 (17.4) 3 (14.3) 0 (0) 0.225
Alcohol, n (%) 6 (26.1) 8 (38.1) 6 (37.5) 0.643
Smoking, n (%) 3 (13.0) 3 (14.3) 1 (6.3) 0.727
Vegetarian, n (%) 10 (43.8) 11 (52.4) 12 (75.0) 0.144
BMI (kg/m2), Mean (±SD) 29.5 (±3.7) 27.6 (±3.7) 27.4 (±4.3) 0.151
Waist Circumference (cm), Mean (±SD) 105.3 (±9.1) 99.0 (±9.9) 100.2 (±8.7) 0.70
ESI, Mean (±SD) 5.9 (±1.6) 5.3 (±1.5) 5.4 (±1.3) 0.412
PGA, Mean (±SD) 3.4 (±0.9) 3.1 (±0.8) 3.2 (±0.8) 0.476
FPG (mg/dl), Mean (±SD) 97.6 (±20.8) 101.9 (±35.1) 103.4 (±28.9) 0.797
Total Cholesterol (mg/dl), Mean (±SD) 184.4 (±37.5) 206.9 (±36.2) 207.2 (±42.3) 0.95
Triglycerides (mg/dl), Mean (±SD) 181.8 (±61.3) 194.3 (±63.1) 200.1 (±55.9) 0.623
HDL (mg/dl), Mean (±SD) 45.1 (±13.5) 44.3 (±6.6) 45.0 (±9.7) 0.968
LDL (mg/dl), Mean (±SD) 107.6 (±35.7) 126.1 (±29.1) 123.1 (±42.3) 0.194
SBP (mmHg), Mean (±SD) 130.4 (±11.5) 130.6 (±12.9) 135.6 (±11.5) 0.344
DBP (mmHg), Mean (±SD) 84.7 (±7.9) 85.9 (±7.9) 85.6 (±8.5) 0.875
Calcium channel blockers, n (%) 5 (21.7) 3 (14.3) 3 (18.6) 0.815
Beta blockers, n (%) 2 (8.7) 1 (4.8) 0 (0) 0.471
Angiotensin receptor blockers, n (%) 2 (8.7) 2 (9.5) 0 (0) 0.456
ACE inhibitors, n (%) 1 (4.3) 0 (0) 1 (6.3) 0.543
Diuretics, n (%) 0 (0) 0 (0) 1 (6.3) 0.247
Sulfonylureas, n (%) 2 (8.7) 0 (0) 1 (6.3) 0.403
Anxiolytics, n (%) 1 (4.3) 1 (4.8) 0 (0) 0.684
Lithium, n (%) 1 (4.3) 0 (0) 0 (0) 0.441
Antidepressants, n (%) 1 (4.3) 2 (9.5) 0 (0) 0.413
Insulin, n (%) 0 (0) 1 (4.8) 0 (0) 0.389
Modafinil, n (%) 0 (0) 1 (4.8) 0 (0) 0.389
NSAIDS, n (%) 0 (0) 1 (4.8) 0 (0) 0.389
Ca, Vitamin D, n (%) 0 (0) 1 (4.8) 0 (0) 0.389
Steroids, n (%) 0 (0) 0 (0) 1 (6.3) 0.247
Beta 2 agonists, n (%) 0 (0) 0 (0) 1 (6.3) 0.247
DM diabetes mellitus, HTN hypertension, BMI body mass index, ESI erythema, scaling and Induration, PFA physician global assessment, FPG fasting plasma glucose,
HDL high density lipoprotein, LDL low density lipoprotein, SBP systolic blood pressure, DBP diastolic blood pressure, ACE inhibitors angiotensin converting
enzyme inhibitors
Values are presented as Mean (±SD) or n (%)
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To the best of our knowledge, effect of metformin in
psoriasis patients with MS as done in our study has not
been explored earlier. Our study has demonstrated im-
proved efficacy of metformin in psoriasis disease itself as
well as features of MS. A population based case control
study Brauchli et al estimated the decreased risk of de-
veloping a first-time psoriasis diagnosis with metformin
use as compared to matched controls [OR = 0.77 (95 %
CI – 0.62–0.96)] [26]. One case of psoriasiform drug
eruption associated with metformin usage has been ob-
served, which on dechallenge and rechallenege leads to
improvement and reappearance of lesions respectively
[27]. In view of the case report, it has to be kept in mind
that there can be clinical worsening of psoriasis with the
use of metformin for treatment of psoriasis.
The anti-proliferative [16, 28], pro-differentiating [29],
anti-inflammatory [11, 12, 30] and anti-angiogenic [31,
32] effects of TZDs seen in other studies may underlie
the observed beneficial anti-psoriatic effects of pioglita-
zone. Metformin act through activation of adenosine
monophosphate-activated protein kinase (AMPK) in
extracellular signal-related kinase (ERK1/2) signaling
pathway leading to cell cycle arrest and therefore inhib-
ition of cell proliferation, hallmark of psoriasis [33].
AMPK activation not only inhibits iNOS, dendritic, T
cell and monocyte/macrophage activation but also acti-
vates IL-10 and TGF-β, thereby exerting its anti-
inflammatory action [34]. The anti-proliferative and
anti-inflammatory action of metformin might have re-



































PASI - 0.001‡, 0.001†, 0.80** 
ESI - 0.002‡, 0.016†, 0.90** 
PGA - 0.008‡, 0.012†, 0.99** 
Fig. 2 Mean change in PASI, ESI and PGA scores in three treatment groups from baseline (Intention to treat Analysis). || = Inter-group
comparisons for PASI, ESI and PGA scores at 12 weeks as compared to baseline was carried out by One Way ANOVA, post hoc test used Scheffe;
† =metformin vs placebo, ‡ = Pioglitazone vs placebo,** = metformin vs pioglitazone. PASI - Psoriasis area and severity index, ESI – Erythema,



































Fig. 3 Percentage of parameters of metabolic syndrome (MS) improved following 12 weeks of treatment in placebo, metformin and pioglitazone
groups from baseline (Intention to treat Analysis). Inter-group comparisons for percentage of parameters of metabolic syndrome improved carried
out by Chi-square test. * = Placebo vs metformin, † = placebo vs pioglitazone, ‡ =metformin vs pioglitazone; MS = Metabolic syndrome
Singh and Bhansali BMC Dermatology  (2016) 16:12 Page 6 of 11
In diabetics, metformin had shown to decrease HbA1C,
total and LDL cholesterol, serum triglycerides, fasting
insulin levels and improves HDL cholesterol [35–37].
Metformin has shown to improve cardiovascular out-
comes by mitigating apoptosis [38]. These results are
similar to the results observed in our study. In our study,
although an increase in mean weight and BMI was
observed with pioglitazone but decrease in mean waist
circumference was also observed. Clinical studies had
shown despite the weight gain reported in all the studies,
which may equal as much as 0.5 kg per month for
monotherapy, mean waist to hip ratio remains invariably
unchanged. In one study, favorable effect on body fat













































PASI - 0.001*, 0.528†, 0.001‡
ESI - 0.001*, 0.729†, 0.001‡
PGA - 0.017*, 0.272†, 0.250‡
Fig. 4 Percentage of patients achieving 75 % reduction in PASI, ESI and PGA scores in placebo, metformin and pioglitazone groups from baseline
(Intention to treat Analysis). Inter-group comparisons for 75 % reduction in PASI, ESI and PGA scores between three treatment groups carried out
by Chi-square test. * = placebo vs metformin, † =metformin vs pioglitazone, ‡ = placebo vs pioglitazone. PASI - Psoriasis area and severity index,
ESI – Erythema, Scaling and Induration, PGA – Physician Global Assessment
Table 2 Mean Change in individual parameters of metabolic syndrome after 12 weeks of treatment in three treatment groups from
baseline (Intention to treat Analysis)
Treatment Placebo (n = 23) Metformin (n = 21) Pioglitazone (n = 16) ANOVA with post hoc
Tukey’s b












Between groups, df = 2, p
value
Weight (kg) −0.6 ± 3.1 0.338 1.1 ± 1.9 0.016f −0.4 ± 1.7 0.324 0.048c, 0.970d, 0.129e
BMI (kg/m2) −0.1 ± 1.4 0.663 0.4 ± 0.7 0.016f −0.2 ± 0.7 0.370 0.186c, 0.995d, 0.210e
Waist circumference
(cm)
−0.9 ± 4.0 0.314 1.9 ± 2.7 0.003f 0.9 ± 2.3 0.119 0.013c, 0.200d, 0.606e
FPG (mg/dl) 2.2 ± 10.0 0.312 15.2 ± 19.2 0.002f 20.5 ± 17.4 <0.001f 0.021c, 0.002d,0.577e
Triglycerides (mg/dl) 1.1 ± 43.3 0.903 44.3 ± 45.4 <0.001f 53.3 ± 36.9 <0.001f 0.004c, 0.001d, 0.798e
HDL (mg/dl) −1.7 ± 6.6 0.221 −1.9 ± 4.6 0.060 −1.5 ± 9.6 0.544 0.992c, 0.994d, 0.974e
SBP (mm Hg) 0.0 ± 8.6 1.000 1.7 ± 6.7 0.257 5.1 ± 6.3 0.005f 0.725c, 0.094d, 0.354e
DBP (mm Hg) 0.3 ± 7.9 0.876 1.7 ± 4.2 0.077 4.1 ± 5.5 0.009f 0.546c, 0.085d, 0.475e
Total Cholesterol
(mg/dl)
1.4 ± 29.2 0.816 21.8 ± 25.2 0.001f 24.0 ± 29.5 0.005f 0.049c, 0.042d, 0.970e
LDL (mg/dl) −5.9 ± 28.3 0.324 6.6 ± 20.0 0.146 9.8 ± 11.6 0.004f 0.151c, 0.079d, 0.898e
FPG fasting plasma glucose, HDL high density lipoprotein, SBP systolic blood pressure, DBP diastolic blood pressure, BMI body mass index, LDL low
density lipoprotein
a Intra-group comparisons for weight, BMI, individual parameters of lipid profile and metabolic syndrome carried out by Paired T-test
b Inter-group comparisons for individual parameters carried out by One way ANOVA, post hoc Tukey’s test
c Metformin vs placebo
d pioglitazone vs placebo
e metformin vs pioglitazone
f statistically significant difference compared to baseline


























IL-6 - 0.568*, 0.872†, 0.328‡
TNF- α - 0.744*, 1.000†, 0.765‡
Fig. 5 Mean decrease in levels of IL-6 and TNF-α in three treatment groups from baseline in subgroup of patients (Intention to treat Analysis). Values
are expressed as Mean ± SD. Inter-group comparisons for IL-6 and TNF-α carried out by One way ANOVA, *- Metformin vs placebo, †- pioglitazone vs
placebo, ‡ - metformin vs pioglitazone, IL-6 – Interleukin-6, TNF-α – Tumor necrosis factor-α
Table 3 Adverse events observed during the study in placebo, metformin and pioglitazone treatment groups in topical treatment
arm
Adverse Event Placebo (N = 23) Metformin (N = 21) Pioglitazone (N = 16) P value (Fischer’s Exact test)
Redness 1 1 0 >0.99a, >0.99b,>0.99c
Pain 1 0 0 >0.99a, >0.99b,>0.99c
Hyperpigmentation 7 5 4 0.74a, >0.99b > 0.99c
Hypopigmentation 0 1 1 0.477a, 0.41b > 0.99c
Exacerbation 2 3 0 0.658a, 0.503b, 0.243c
Hypothyroidism 1 0 0 >0.99a, >0.99b
Edema 0 0 2 0.162b, 0.180c
c/o Weight Gain 0 0 2 0.162b, 0.180c
Anemia 0 0 0 -
Abdominal Pain 0 1 0 0.477a, >0.99c
Headache 0 0 0 -
Gastritis 0 0 0 -
Nausea 0 0 0 -
Vomiting 0 0 0 -
Dizziness 0 0 0 -
Diarrhea 0 1 0 0.477a, >0.99c
Heartburn 0 1 0 0.477a, >0.99c
>3 times SGOT/SGPT 0 0 0 -
Slight increase in SGOT/SGPT 0 0 0 -
Increased TLC 0 0 0 -
Weight gain > 1 kg 8 3 8 0.169a, 0.509b, 0.030c
Recurrence after 3 months 4 6 5 0.377a, 0.312b, 0.860c
Inter group comparison between groups was done by Fischer’s Exact test; p – value ≤ 0.05 was considered statistically significant
a placebo vs metformin
b placebo vs pioglitazone
c metformin vs pioglitazone
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II diabetes were treated with pioglitazone 45 mg/day for
16 weeks [39]. MR imaging revealed that pioglitazone
decreased visceral fat area and increased subcutaneous
fat mass. With 1H-MR spectroscopy in same group of
patients, significant decrease in liver fat content was
demonstrated. Thus, thiazolidinedione’s (TZDs) have fa-
vorable effects on body fat distribution, intra hepatic fat
content and adipose tissue metabolism, all resulting in
increased insulin sensitivity.
Our study had revealed a mean fall of 20.5 mg/dl in
FPG in psoriasis patients with MS with pioglitazone
30 mg/day. PROFIT-J study have shown improvement in
glycemic control, DBP and lipid profile [40]. In clinical tri-
als, pioglitazone monotherapy at a dose of 30 mg/day re-
vealed a dose dependent lowering of FPG by 1.0–
3.1 mmol/L and HbA1C reductions ranging between 0.3
and 1.08 % from baseline, significant when compared with
placebo [41–45]. Pioglitazone increases peripheral insulin
sensitivity, enhancing both splanchnic and peripheral glu-
cose uptake, in patients with type II diabetes in random-
ized, placebo controlled, 12–26 weeks trial [40, 46, 47].
We observed a mean decrease in serum triglycerides, total
cholesterol and LDL cholesterol of 53.3, 24 and 9.8 mg/dl
respectively, with pioglitazone 30 mg/day. Lipid profiles
generally improved in pioglitazone recipients in three pla-
cebo controlled 12–26 week trial [41, 42, 48]. Favorable
increases in HDL cholesterol were greater in pioglitazone
than placebo recipients in three trials [40, 42, 48].
Mean reduction in SBP and DBP of 5.1 and 4.1 mmHg
respectively was measured in pioglitazone group in our
study, which was significant as compared to baseline. In
a review article by Giles et al, the observed magnitude of
reduction was 4–5 mmHg in SBP and 2–4 mmHg in
DBP, which were sufficient to significantly reduce car-
diovascular event rates [49]. The decrease in cardiovas-
cular risk factors namely lipid profile and blood pressure
in our study might contribute to the overall decrease in
diabetes and cardiovascular mortality in psoriasis pa-
tients with MS.
Increased risk of bladder cancer with the long term
use of pioglitazone as shown in French cohort study
[50], UK nested case control study [51] and interim re-
sults of longitudinal study [52]. However, the 10-year
final analysis of longitudinal study [52] did not show any
statistically significant findings of increased risk of blad-
der cancer with long term use of pioglitazone [53]. Simi-
larly, no statistically significant association was found in
two Taiwanese studies [54, 55]. Infact, TZDs have shown
to decrease the risk of breast, brain, colorectal, ear-nose-
throat, kidney, liver, lung, lymphatic, prostate, stomach
and uterus cancer significantly [56]. FDA although is-
sued a safety warning, has not withdrawn the drug.
There are no significant differences in metformin as
compared to pioglitazone with regard to improvement
in psoriasis and MS parameters. But there is significant
reduction in weight with the use of metformin and due
to controversy of increased risk of bladder cancer associ-
ated with pioglitazone; metformin can be preferred over
pioglitazone in psoriasis patients with MS.
In subgroup analysis, 10 % of patients in placebo,
14.3 % in metformin and 37.5 % of patients in pioglita-
zone subgroup had no decline or rather increase in the
levels of IL-6 and TNF-α, consistent with the relapse of
psoriasis in these patients in next 6 months. Remitting
relapsing nature of the disease might be accounted for
no significant change in the IL-6 and TNF-α level.
Randomization and placebo control are the strengths of
our study. The study also has some limitations. Intermedi-
ate dose of pioglitazone (30 mg/day) and metformin
(1000 mg/day) was used in the study. Secondly, it was an
open label study, although blinded end point assessment
was done.
Conclusion
Insulin sensitizers have shown improvement in the pa-
rameters of MS as well as psoriasis disease. With further
evaluation in clinical studies, Insulin sensitizers can be
used for the management of psoriasis patients with MS.
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